JP2020518240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518240A5 JP2020518240A5 JP2019559009A JP2019559009A JP2020518240A5 JP 2020518240 A5 JP2020518240 A5 JP 2020518240A5 JP 2019559009 A JP2019559009 A JP 2019559009A JP 2019559009 A JP2019559009 A JP 2019559009A JP 2020518240 A5 JP2020518240 A5 JP 2020518240A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- targeting
- protein
- endolysosome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims 37
- 210000004027 cell Anatomy 0.000 claims 22
- 239000012634 fragment Substances 0.000 claims 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 10
- 238000010494 dissociation reaction Methods 0.000 claims 10
- 230000005593 dissociations Effects 0.000 claims 10
- 108020001580 protein domains Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000001723 extracellular space Anatomy 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 3
- 230000002378 acidificating effect Effects 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 2
- -1 antibody domains Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000007721 medicinal effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 210000001163 endosome Anatomy 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 229960002087 pertuzumab Drugs 0.000 description 4
- 229960001612 trastuzumab emtansine Drugs 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Images
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023041511A JP7832906B2 (ja) | 2017-01-17 | 2023-03-16 | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
| JP2025147594A JP2026000961A (ja) | 2017-01-17 | 2025-09-05 | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447265P | 2017-01-17 | 2017-01-17 | |
| US201762447411P | 2017-01-17 | 2017-01-17 | |
| US62/447,411 | 2017-01-17 | ||
| US62/447,265 | 2017-01-17 | ||
| PCT/US2018/013952 WO2018136455A1 (en) | 2017-01-17 | 2018-01-17 | Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023041511A Division JP7832906B2 (ja) | 2017-01-17 | 2023-03-16 | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020518240A JP2020518240A (ja) | 2020-06-25 |
| JP2020518240A5 true JP2020518240A5 (https=) | 2021-02-25 |
Family
ID=62908641
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559009A Pending JP2020518240A (ja) | 2017-01-17 | 2018-01-17 | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
| JP2023041511A Active JP7832906B2 (ja) | 2017-01-17 | 2023-03-16 | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
| JP2025147594A Pending JP2026000961A (ja) | 2017-01-17 | 2025-09-05 | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023041511A Active JP7832906B2 (ja) | 2017-01-17 | 2023-03-16 | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
| JP2025147594A Pending JP2026000961A (ja) | 2017-01-17 | 2025-09-05 | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11690919B2 (https=) |
| EP (1) | EP3570894A4 (https=) |
| JP (3) | JP2020518240A (https=) |
| CN (1) | CN110944672A (https=) |
| AU (2) | AU2018210912A1 (https=) |
| CA (1) | CA3050692A1 (https=) |
| WO (1) | WO2018136455A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020160310A1 (en) * | 2019-01-30 | 2020-08-06 | The Wistar Institute Of Anatomy And Biology | Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics |
| CN110893236A (zh) * | 2019-10-09 | 2020-03-20 | 中山大学 | 溶酶体靶向的抗体药物偶联物及其应用 |
| EP4228694A4 (en) * | 2020-10-15 | 2024-12-18 | Janux Therapeutics, Inc. | ANTIBODIES DIRECTED AGAINST PSMA AND CD3 AND USES THEREOF |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| CN112807444B (zh) * | 2021-01-18 | 2023-12-12 | 北京大学深圳研究生院 | 一种纳米抗体药物偶联物 |
| PT4288456T (pt) | 2021-02-03 | 2024-11-13 | Mythic Therapeutics Inc | Anticorpos anti-met e suas utilizações |
| WO2022194078A1 (zh) * | 2021-03-15 | 2022-09-22 | 北京大学 | 用于靶分子修饰的缀合物及其制备方法 |
| US20250339571A1 (en) * | 2021-08-27 | 2025-11-06 | Actinium Pharmaceuticals, Inc. | Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer |
| WO2024046468A1 (en) * | 2022-09-02 | 2024-03-07 | Nanjing Legend Biotech Co., Ltd. | Fusion proteins targeting lysosomal degradation pathway |
| CN118903457A (zh) * | 2023-05-08 | 2024-11-08 | 中国科学院过程工程研究所 | 基于溶酶体的抗病毒制剂及其制备方法和用途 |
| CN117659185B (zh) * | 2023-12-06 | 2024-08-02 | 无锡傲锐东源生物科技有限公司 | 抗人Caldesmon蛋白单克隆抗体及其杂交瘤细胞株和应用 |
| WO2025229338A2 (en) | 2024-05-03 | 2025-11-06 | University Of Southampton | An antibody or antibody fragment |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635680B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
| US7645739B2 (en) * | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
| US20040022731A1 (en) * | 2002-04-26 | 2004-02-05 | Alexei Bogdanov | In vivo imaging of apoptosis |
| US20090181048A1 (en) | 2007-06-08 | 2009-07-16 | The Regents Of The University Of California | Cancer drug delivery using modified transferrin |
| GB0807831D0 (en) * | 2008-04-29 | 2008-06-04 | Cambridge Entpr Ltd | Agents for imaging cell death |
| SG183867A1 (en) * | 2010-03-11 | 2012-10-30 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| EP3680251A1 (en) * | 2011-09-30 | 2020-07-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules for promoting elimination of antigens |
| JP6124800B2 (ja) * | 2011-11-30 | 2017-05-10 | 中外製薬株式会社 | 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬 |
| EP2612864A1 (en) | 2012-01-06 | 2013-07-10 | University College Dublin | Affinity tag system |
| CA2873112A1 (en) | 2012-05-11 | 2013-11-14 | Alexander Krantz | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
| CA2871116A1 (en) * | 2012-05-14 | 2013-11-21 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| CA2895284A1 (en) * | 2013-02-07 | 2014-08-14 | Immunomedics, Inc. | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| KR20160043927A (ko) * | 2013-03-14 | 2016-04-22 | 파카쉬 길 | 세포 표면 grp78에 결합하는 항체를 사용하는 암 치료 |
| US20160031985A1 (en) | 2013-03-15 | 2016-02-04 | Katherine S. Bowdish | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use |
| WO2015048724A1 (en) * | 2013-09-30 | 2015-04-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for self-assembly system of nanoparticles and microparticles for multi-targeting specificity |
| JP2017510548A (ja) * | 2014-01-29 | 2017-04-13 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途 |
| CN106459192B (zh) | 2014-06-30 | 2021-08-03 | 默克专利股份公司 | 具有pH依赖性抗原结合的抗TNFa抗体 |
| JP6967528B2 (ja) * | 2016-04-04 | 2021-11-17 | バイオベラティブ ユーエスエー インコーポレイテッド | 抗補体Ｂｂ因子抗体及びその使用 |
| JP7295799B2 (ja) | 2016-12-02 | 2023-06-21 | ザ テキサス エー アンド エム ユニバーシティー システム | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
-
2018
- 2018-01-17 US US16/478,821 patent/US11690919B2/en active Active
- 2018-01-17 CN CN201880018641.6A patent/CN110944672A/zh active Pending
- 2018-01-17 CA CA3050692A patent/CA3050692A1/en active Pending
- 2018-01-17 WO PCT/US2018/013952 patent/WO2018136455A1/en not_active Ceased
- 2018-01-17 AU AU2018210912A patent/AU2018210912A1/en not_active Abandoned
- 2018-01-17 EP EP18742102.9A patent/EP3570894A4/en active Pending
- 2018-01-17 JP JP2019559009A patent/JP2020518240A/ja active Pending
-
2023
- 2023-03-16 JP JP2023041511A patent/JP7832906B2/ja active Active
- 2023-05-16 US US18/318,062 patent/US20230390413A1/en active Pending
-
2025
- 2025-01-11 AU AU2025200221A patent/AU2025200221A1/en active Pending
- 2025-09-05 JP JP2025147594A patent/JP2026000961A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518240A5 (https=) | ||
| US12343401B2 (en) | Modular self assembly disassembly (SADA) technologies | |
| US11999801B2 (en) | Multispecific antibodies | |
| JP7690285B2 (ja) | 結合タンパク質１ | |
| Wu et al. | Designer genes: recombinant antibody fragments for biological imaging | |
| Hudson | Recombinant antibody constructs in cancer therapy | |
| CN108136012B (zh) | 靶向分子的抗原结合构建体 | |
| JP2025163055A5 (https=) | ||
| JP7832906B2 (ja) | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート | |
| JP2003502030A5 (https=) | ||
| Hong et al. | Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy | |
| AU2017293450B2 (en) | Humanized antibodies transmigrating the blood-brain barrier and uses thereof | |
| Verhaar et al. | A single chain Fv derived from a filamentous phage library has distinct tumour targeting advantages over one derived from a hybridoma | |
| CN108866635B (zh) | 多特异性蛋白药物及其文库、以及制备方法和应用 | |
| US20220056146A1 (en) | Antibodies and Antigen Binding Fragments Against CD155 Methods of Use Thereof | |
| Chester et al. | Clinical applications of phage‐derived sFvs and sFv fusion proteins | |
| Kim et al. | Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imaging | |
| Albrecht et al. | Update: Recombinant antibodies: From the laboratory to the clinic | |
| JP2025528390A (ja) | 抗モノメチルアウリスタチン抗体および抗体フラグメント | |
| Zahid et al. | Single chain fragment variable, a new theranostic approach for cardiovascular diseases | |
| JP4443923B2 (ja) | 親和性向上剤 | |
| JP2024531426A (ja) | Ｃｄ１５５に対する抗体および抗原結合フラグメント、その使用方法 | |
| JP7378088B2 (ja) | ｈＥＲＧ１およびｈＥＲＧ１／インテグリンβ１に結合する単一特異性および二重特異性抗体 | |
| JPWO2022104236A5 (https=) | ||
| US20240316213A1 (en) | Antibody-protamine fusions as targeting compounds of a protamine-based nanoparticle |